Metatron (OTC:MRNJ), a mobile and web technology pioneer having developed over 2000 apps on iTunes and Google Play today it announced that it has created an online retail store for CBD product sales for the famous San Diego CBD retailer Smoke Shop and Gifts (SSG).
The already mobile friendly store is located at https://www.smokeshopandgifts.com. The native app versions are expected to appear on iTunes and Google Play within the next few weeks.
New customers can receive 10% off their first order by using the code SSG10 upon checkout.
Metatron was the first company to ever have a CBD related app on iTunes. A new analysis by the Brightfield Group estimates that the CBD market could explode to $22 Billion by 2022, outpacing marijuana.
At SSG, Excellent Customer Service and Extreme Product Quality is their #1 Priority. SSG was founded in 2016 with the vision of providing the highest quality hemp flower and CBD for daily use. After a long journey and years of searching, they found the perfect Hemp farms that shared SSGs vision. Working closely with these farms, they were able to source high-grade CBD hemp flower that is legal, testing with less than the U.S.-allowed .3% Delta 9 THC.
If you ever visit beautiful San Diego, be sure to patronize SSG retail locations and meet the most friendly, knowledgeable CBD expert team on the West Coast.
In 2018, the Farm Bill was signed into law and removed hemp from the Controlled Substances Act, clarifying hemps legal status in the U.S. Consumers across the country can now purchase CBD products in stores and online.
In other recent news Metatron released Holo Ball with Krave Games LLC which is currently available on the iTunes app store with a 4.5 star rating. The free ad-supported game can be downloaded at http://bit.ly/HoloBallFree. The company expects to release more games in the near future.
Google Play: http://bit.ly/1O64fX9
Forward-Looking Statements: Any statements made in this press release which are not historical facts contain certain forward-looking statements, as such term is defined in the Private Litigation Reform Act of 1995, concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results of the specific items described in this release, and the company’s operations generally, to differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company’s need for additional financing, which is not assured and which may result in dilution of shareholders, the company’s status as a small company with a limited operating history, dependence on third parties and the continuing popularity of the iOS operating system, general market and economic conditions, technical factors, receipt of revenues, and other factors, many of which are beyond the control of the company. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of such statements, and we disclaim any obligation to update information contained in any forward looking statement. Metatron retained Global Discovery Group Inc. for $30,500 for consulting services, $25,000 with Digital Agency, Inc for social media services along with CSC Partners for $1,500, Bas1 for $2501 and the company retained Pacific Equity Alliance LLC by issuing Integrative Business Alliance LLC 100m rule 144 for 1 year consulting services. Metatron does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. CBD has not been evaluated by the food and drug administration (FDA). CBD products are not intended to diagnose, treat, cure or prevent any disease.